Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B

Liver International

Volumn 27, Issue 7, 2007, Pages 969-976

  Kim, Beom Kyung ^a   Kim, Sung Ae ^a   Park, Young Nyun ^a,b,c   Cheong, Jae Youn ^b,c   Kim, Hwa Sook ^a,b   Park, Jun Yong ^a,b   Cho, Sung Won ^b,d   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Moon, Young Myoung ^a   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Brain Korea 21 Project for Medical Science   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Biopsy; Diagnosis; Fibrosis; Hepatitis B; Platelet; Spleen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SPLEEN SIZE; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; DISEASE PROGRESSION; ENZYME TESTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPLEEN;

EID: 34547857433     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01519.x     Document Type: Article

References (35)

1. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101(Suppl. 1): S1-6.
2. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 99: 1160-74.
3. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
4. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
5. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
6. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
7. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
8. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepatol 2002; 9: 128-33.
9. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-93.
10. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 1704-13.
11. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
12. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
13. Forns X, Ampurdan S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
14. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: Use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 2328-32.
15. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
16. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepatol 1997; 4: 199-208.
17. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
18. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple. Hepatology 2003; 38: 1312-3; author reply 3.
19. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: A comparison of two scoring systems. J Hepatol 2003; 38: 223-9.
20. Forns X, Ampurdan S, Sanchez-Tapias JM, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35: 265-71.
21. Bravo AA, Sheth SG, Chopra S. Liver biopsy. NEJM 2001; 344: 495-500.
22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
23. Dittrich M, Milde S, Dinkel E, Baumann W, Weitzel D. Sonographic biometry of liver and spleen size in childhood. Pediatr Radiol 1983; 13: 206-11.
24. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-30.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
26. Craxi A, Antonucci G, Camma C. Treatment options in HBV. J Hepatol 2006; 44: S77-S83.
27. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
28. Aube C, Oberti F, Korali N, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-8.
29. Sim SJ CJ, Cho SW, Kim JS, et al. Efficacy of AST to platelet ratio index in predicting severe hepatic fibrosis and cirrhosis in chronic hepatitis B virus infection. Korean J Gastroenterol 2005; 45(5): 340-7.
30. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13: 317-23.
31. Cioni G, Tincani E, D'Alimonte P, et al. Relevance of reduced portal flow velocity, low platelet count and enlarged spleen diameter in the non-invasive diagnosis of compensated liver cirrhosis. Eur J Med 1993; 2: 408-10.
32. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
33. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
34. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006; 26: 666-72.
35. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.